Biopharmaceutical Industry Outlook:
Impact of New Balance of Power in Washington D.C.
Impact of New Balance of Power in Washington D.C.
Rising drug prices have been on voters’ and legislators’ minds recently, as it appears that it’s becoming increasingly difficult for many Americans to afford their medications. CFRA believes that drug prices may not be a primary driver of mounting health care costs in the US; however, we suspect that legislators are aware of that.
During this webinar, we covered competitive factors impacting drug pricing, highlighted trends in the biopharmaceutical industry, and discussed potential legislation that could come out of Washington D.C. related to the drug industry. While sentiment towards drug manufacturers has been negative because of the public focus on drug pricing, we don’t expect any unfavorable legislation to be passed in the near future.
Presented by:
Moderated by:
Ken Leon, CFRA Director of Equity Research